Shannon Kasperbauer, MD

Shannon Kasperbauer, MD

Associate Professor of Medicine
Department of Medicine
Division of Mycobacterial & Respiratory Infections
National Jewish
Denver, Colorado

Related Videos

What are the characteristics and/or risk factors that predispose patients to MAC lung infection? And what species are particularly relevant and widespread causative pathogens in NTM lung disease? Video

What are the characteristics and/or risk factors that predispose patients to MAC lung infection? And what species are particularly relevant and widespread causative pathogens in NTM lung disease?

Once you’ve decided to deploy the FDA-approved amikacin liposome inhaled aerosol suspension in patients with refractory MAC lung disease, how do you use to optimize patient adherence, tolerability and compliance with this treatment? Video

Once you’ve decided to deploy the FDA-approved amikacin liposome inhaled aerosol suspension in patients with refractory MAC lung disease, how do you use to optimize patient adherence, tolerability and compliance with this treatment?

Can you summarize the current evidence for amikacin liposome inhaled suspension, the patients in which it is appropriately deployed, and what supportive and educational measures improve toleration, adherence and durability of long-term treatment? Video

Can you summarize the current evidence for amikacin liposome inhaled suspension, the patients in which it is appropriately deployed, and what supportive and educational measures improve toleration, adherence and durability of long-term treatment?

What have you learned about the role of and approach to using amikacin liposome aerosol suspension from the previous—and similar other—cases of MAC lung disease that you have managed? Video

What have you learned about the role of and approach to using amikacin liposome aerosol suspension from the previous—and similar other—cases of MAC lung disease that you have managed?

Can you share a specific case that exemplifies at least one clinical phenotype with MAC lung disease that is appropriately managed with amikacin liposome inhaled suspension? Video

Can you share a specific case that exemplifies at least one clinical phenotype with MAC lung disease that is appropriately managed with amikacin liposome inhaled suspension?

What were the conclusions of the NTM-NET Consensus Guidelines as far as the definition of treatment refractoriness in MAC lung disease, and what’s your assessment of these recommendations? Video

What were the conclusions of the NTM-NET Consensus Guidelines as far as the definition of treatment refractoriness in MAC lung disease, and what’s your assessment of these recommendations?

When intensification of therapy with amikacin is being considered, or has been implemented in patients, how do you differentiate between and/or decide to initiate therapy with the IV vs. amikacin liposome inhalation suspension formulation? Video

When intensification of therapy with amikacin is being considered, or has been implemented in patients, how do you differentiate between and/or decide to initiate therapy with the IV vs. amikacin liposome inhalation suspension formulation?

What is the role of molecular diagnostics and speciating NTM organisms as part of the microbiological characterization for MAC lung infection? Video

What is the role of molecular diagnostics and speciating NTM organisms as part of the microbiological characterization for MAC lung infection?

Why is continuous airway clearance an important pillar of therapy for patients with MAC lung disease? Video

Why is continuous airway clearance an important pillar of therapy for patients with MAC lung disease?